首页> 美国卫生研究院文献>other >Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized Double-blind Placebo-Controlled Trial

【2h】

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized Double-blind Placebo-Controlled Trial

机译：复发/难治性CLL患者的依达拉西布或安慰剂联合苯达莫司汀和利妥昔单抗-3期随机双盲安慰剂对照试验的中期结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 other
作者
Andrew D. Zelenetz; Jacqueline C. Barrientos; Jennifer R. Brown; Bertrand Coiffier; Julio Delgado; Miklós Egyed; Paolo Ghia; Árpád Illés; Wojciech Jurczak; Paula Marlton; Marco Montillo; Franck Morschhauser; Alexander S. Pristupa; Tadeusz Robak; Jeff P. Sharman; David Simpson; Lukáš Smolej; Eugen Tausch; Adeboye H. Adewoye; Lyndah K. Dreiling; Yeonhee Kim; Stephan Stilgenbauer; Peter Hillmen;
展开▼
作者单位

展开▼
年(卷),期 -1(18),3
年度 -1
页码 297–311
总页数 29
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial [J] . Zelenetz Andrew D., Barrientos Jacqueline C., Brown Jennifer R., The lancet oncology . 2017 ,第3期

机译：伊德利罗丽金或安慰剂与Bendamustine和Rituximab的复发或难治性慢性淋巴细胞白血病患者组合：中期结果来自第3期，随机，双盲，安慰剂对照试验
2. Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL [J] . Zelenetz Andrew D., Brown Jennifer R., Delgado Julio, Blood: The Journal of the American Society of Hematology . 2016 ,第22期

机译：艾达西单抗联合苯达莫司汀和利妥昔单抗治疗复发/难治性CLL患者的III期随机研究总生存率的最新分析
3. ASCEND Phase 3 study of acalabrutinib versus investigator's choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) [J] . Ghia Paolo, Pluta Andrzej, Wach Malgorzata, Leukemia and lymphoma . 2020 ,第S1期

机译：Ascend第3阶段3 acalabrutinib与调查患者选择Rituximab Plus Idelalisib（IDR）或Bendamustine（Br）的复发/难治性（R / R）慢性淋巴细胞白血病（CLL）的选择
4. EFFECT OF TARGETED PULSED ELECTROMAGNETIC FIELD THERAPY ON CANINE POST-OPERATIVE HEMILAMINECTOMY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL [C] . ACVS Veterinary Symposium . 2018

机译：靶向脉冲电磁场治疗对犬术后血栓切除术的影响：双盲，随机，安慰剂对照临床试验
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia [O] . Steven E. Coutre, Ian W. Flinn, Sven de Vos, 2018

机译：依达拉西布联合利妥昔单抗或苯达莫司汀或两者联合用于复发/难治性慢性淋巴细胞白血病患者
7. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial [O] . Zelenetz, Andrew D., Barrientos, Jacqueline C., Brown, Jennifer R., 2017

机译：Idelalisib或安慰剂与苯达莫司汀和利妥昔单抗联合用于复发或难治性慢性淋巴细胞白血病患者：3期随机，双盲，安慰剂对照试验的中期结果

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized Double-blind Placebo-Controlled Trial

著录项

相似文献

相关主题

期刊订阅